首页> 外文期刊>The journal of clinical psychiatry >Behavioral and Emerging Pharmacologic Treatment Options for Cognitive Impairment in Schizophrenia
【24h】

Behavioral and Emerging Pharmacologic Treatment Options for Cognitive Impairment in Schizophrenia

机译:精神分裂症的认知障碍的行为和新兴药物治疗选择

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years, the goal of treatment for individuals with schizophrenia has shifted from symptom control to functional recovery. For recovery to occur, the substantial cognitive impairments associated with this disorder must be addressed. Advances in neuroscience have paved the way for the development of more effective behavioral and pharmacologic treatments. Behavioral interventions such as cognitive training are tapping into the innate plasticity and adaptive qualities of the brain. Emerging pharmacologic treatments are targeting new neurotransmitters and systems, such as the glutamatergic system and the nicotinic-cholinergic system, which are involved in the cognitive and sensory deficits that lead to impairment. The best chances for recovery will most likely occur by combining behavioral and pharmacologic interventions.
机译:近年来,精神分裂症患者的治疗目标已从症状控制转向功能恢复。为了使恢复发生,必须解决与该疾病有关的实质性认知障碍。神经科学的进步为开发更有效的行为和药物治疗铺平了道路。诸如认知训练之类的行为干预正在利用大脑固有的可塑性和适应能力。新兴的药物治疗针对的是新的神经递质和系统,例如谷氨酸能系统和烟碱胆碱能系统,它们参与导致损害的认知和感觉缺陷。结合行为和药物干预措施,才有可能获得最大的康复机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号